13.4 C
Brussels
Thursday, October 5, 2023
NewsHealth Union: a stronger role for the European Medicines Agency

Health Union: a stronger role for the European Medicines Agency

DISCLAIMER: Information and opinions reproduced in the articles are the ones of those stating them and it is their own responsibility. Publication in The European Times does not automatically means endorsement of the view, but the right to express it.

DISCLAIMER TRANSLATIONS: All articles in this site are published in English. The translated versions are done through an automated process known as neural translations. If in doubt, always refer to the original article. Thank you for understanding.

More from the author

Free movement: Schengen reform to ensure border controls only as a last resort

Free movement: Schengen reform to ensure border controls only as a last resort

0
The reform of border controls within the free movement Schengen area can only be reintroduced when absolutely necessary.
Reducing pollution in EU groundwater and surface waters

Reducing pollution in EU groundwater and surface waters

0
Parliament adopted its position on reducing groundwater and surface waters pollution and improving EU water quality standards.
Critical raw materials - plans to secure EU supply and sovereignty

Critical raw materials – plans to secure EU supply and sovereignty

0
Electric cars, solar panels and smartphones - all of them contain critical raw materials. They are the lifeblood of our modern societies.

The EU will be better prepared to manage future health crises by tackling shortages of medicines and medical devices more effectively.

Parliament endorsed the provisional agreement reached with the Council last year on increasing the powers of the EU’s medicines regulator with 655 votes in favour, 31 against and 8  abstentions.

The European Medicines Agency (EMA) will be better equipped to monitor and mitigate shortages of medicinal products and medical devices considered to be critical in order to address public health emergencies. Two “shortages steering groups”, for medicines and medical devices respectively, will be created and the EMA will set up and manage the European Shortages Monitoring Platform to facilitate data collection.

All actors in the supply chain will be involved more closely, including expert advice from observers representing patients and medical professionals, as well as marketing authorisation holders, wholesale distributors or any other relevant healthcare stakeholders.

The agency will also set up a public webpage with information on shortages. Data related to clinical trials and product information on authorised medicinal products will be made available more timely and transparently.

Quote

Rapporteur Nicolás González Casares (S&D, ES) said:

“The new regulation makes both the Agency and all actors in the supply chain more transparent, involving them more in the process and fostering synergies between EU agencies. Moreover, we pave the way to promoting clinical trials for the development of vaccines and treatments, boosting transparency on those issues. And, with the new European Shortages Monitoring Platform, we provide the Agency with a key tool to monitor medicines supply and prevent shortages. In short, more transparency, more participation, more coordination, more effective monitoring and more prevention.”

Next steps

Following the final vote in plenary, the text will be published in the EU Official Journal shortly after. The regulation will apply as of 1 March 2022.

Background

As part of building a European Health Union, the Commission proposed on 11 November 2020 a new health security framework fit for future health challenges, based on lessons learnt from combatting COVID-19, which includes a proposal to increase the powers of the European Medicines Agency.

- Advertisement -
- EXCLUSIVE CONTENT -spot_img
- Advertisement -
- Advertisement -
- Advertisement -

Must read

Latest articles

- Advertisement -